The new president of Japan's Riken research institute vowed to enter into partnerships with more businesses as part of his plan for reform of the institution hit by a scandal over its stem cell research.
China health authorities have proposed some new regulations for conducting stem-cell clinical trials in the country, one requiring that a 30-year archive of the clinical records of stem-cell donors and patients be maintained.
Scientists at the Scripps Research Institute say they've identified an enzyme necessary for maintaining the stability of hematopoietic stem cells.
Researchers in Japan said they have been able to stop the deterioration associated with muscular dystrophy by creating stem cells and implanting them in a mouse.
A group of bioengineers at UC Berkeley has been hard at work hatching a new "heart-on-a-chip" technology that aims to offer researchers a better, less expensive way to develop new drugs.
Investigators say that they've identified a pathway that can be used to target brain tumor stem cells, adding to potential therapeutic strategies for the aggressive disease glioblastoma.
Scientists say that they have developed a method to use modified messenger RNA to lengthen telomeres, opening a pathway to countering the effects of aging in cells--a process that might apply to a range of diseases from DMD to diabetes and heart disease.
Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.
CRISPR technology's potential for gene editing has helped inspire the launch of a trio of closely watched biotech startups with their sights set on some cutting-edge approaches to new therapeutics. And now a team at Johns Hopkins has done some experiments to demonstrate its promise in engineering human stem cell therapies.
Two prominent researchers whose work on stem cells has come under review have fired back at Harvard Medical School and Brigham & Women's Hospital in a lawsuit, blaming a coauthor for the problems that triggered one paper to be retracted and another questioned while claiming that the university mishandled its investigation into their efforts.